See Recent Shionogi-Sponsored Congress Presentations
Congresses
As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.
Looking for a specific congress? Use the Search feature above to find content by keyword, author, title, disease state, medicine, or compound. Please note that Search functions site-wide and will take you to a separate results page.
The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Select a congress event or filter to view available congress presentations.
You Are Viewing Presentations
Activity of cefiderocol against carbapenem-nonsusceptible gram-negative isolates from skin and soft tissue infections in US and European medical centers collected as part of the SENTRY antimicrobial surveillance program (2020–2024)
Activity of cefiderocol against carbapenem-nonsusceptible gram-negative isolates from skin and soft tissue infections in US and European medical centers collected as part of the SENTRY antimicrobial surveillance program (2020–2024)
Activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023)
Activity of cefiderocol against carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023)
Activity of cefiderocol against carbapenem-resistant and molecularly characterized Enterobacterales isolates causing infections in hospitals in Europe and adjacent regions (2020–2023)
Activity of cefiderocol against carbapenem-resistant and molecularly characterized Enterobacterales isolates causing infections in hospitals in Europe and adjacent regions (2020–2023)
Activity of cefiderocol against carbapenem-resistant Pseudomonas aeruginosa encountered in each of the different United States Census Bureau divisions
Activity of cefiderocol against carbapenem-resistant Pseudomonas aeruginosa encountered in each of the different United States Census Bureau divisions
Activity of cefiderocol against carbapenem-resistant Pseudomonas aeruginosa, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023)
Activity of cefiderocol against carbapenem-resistant Pseudomonas aeruginosa, including molecularly characterized clinical isolates, causing infections in hospitals in European and adjacent regions (2020–2023)
Activity of cefiderocol against clinical isolates of Acinetobacter baumannii complex collected from five European countries as part of
the SENTRY antimicrobial surveillance programme 2020–2023
Activity of cefiderocol against clinical isolates of Acinetobacter baumannii complex collected from five European countries as part of
the SENTRY antimicrobial surveillance programme 2020–2023
You Are Viewing Congress Locations
NEALS 2026
IDWeek 2026
ASM Microbe 2026
ESPID 2026
AAN 2026
ESCMID 2026
CROI 2026
GSA 2025
APCCMI 2025
ASCP 2025
NACFC 2025
IDWeek 2025
AVG and IMRP 2025
ASM Microbe 2025
ESCMID 2025
ISIRV 2025
CROI 2025
